With multiple academic drug discovery centers in the US and around the world developing compounds for AD and other CNS indications, there is an opportunity to pull together a library of optimized compounds from a wide variety of programs. Here we propose a simple program whereby screening and early stage drug discovery groups with a significant interest in neurodegenerative, psychiatric and other CNS disorders, deposit into a central repository compounds that have shown significant CNS-relevant activity. This relatively small but highly selective library of active and relevant compounds will then be made available to academic drug discovery centers with the intention that they each include the shared library in their ongoing screening. This will increase the exposure of the shared library compounds to a wide range of assays, possibly identifying novel activities for the compounds. This initiative is intended as a low cost and administratively simple way to maximize drug discovery efforts within the neuroscience community. Whereas the program is initially envisioned as an academic collaboration, if successful it can be scaled to include biotech and other interested parties.